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Abstract
 
Reactivation of dormant infections causes an immense burden of morbidity and mortality in
the world at large. Reactivation can occur as a result of immunosuppression, environmental
insult, or aging; however, the cause of reactivation of such infections is often not clear. We
have previously shown that persistence of the parasite 
 
Leishmania major
 
 is controlled by endog-
enous CD4
 
  
 
CD25
 
  
 
regulatory T (T reg) cells. In this report, we show that despite efficient
parasite clearance at secondary sites of infection, 
 
Leishmania
 
 superinfection can cause disease
reactivation at the primary site. Our results strongly suggest that T reg cells, whose numbers
increase in sites of reactivation, are directly responsible for such reactivation. Depletion of
CD25
 
  
 
cells at the time of secondary challenge prevented disease reactivation at the site of per-
sistent infection while strengthening the expression of immunity at the site of secondary chal-
lenge. Finally, transfer of T reg cells purified from infected mice into chronically infected mice
was sufficient to trigger disease reactivation and prevent the expression of an effector memory
response. Our results demonstrate that after persistence is achieved, an equilibrium between T
reg cells and effector lymphocytes, which can be disturbed by superinfection, controls the effi-
ciency of recall immune responses and disease reactivation.
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Introduction
 
A large number of infectious diseases that have severe con-
sequences for human health (e.g., tuberculosis, leishmaniasis,
toxoplasmosis, and herpes virus infections) are caused by
pathogens that also produce persistent infections. Reactivation
of such infections causes an immense burden of morbidity
and mortality in the world at large. Reactivation commonly
occurs under conditions of immunosuppression, but can
also result from environmental insults and/or advancing
age, presumably as a consequence of perturbing the immune
system. However, a defined cause for reactivation or acti-
vation of infections is often not clear. More broadly, the
mechanisms underlying the negotiation of latency by host
and microbial organism, and particularly those underlying
the breaking of latency, remain poorly understood. In human
leishmaniasis, persistent infection follows self-cure or suc-
cessful chemotherapy (1, 2). Such persistence often gives
rise to disease reactivation including visceral leishmaniasis
associated with HIV coinfection (3), post-kala-azar dermal
leishmaniasis after cure of visceral leishmaniasis (4, 5), reac-
tivation of localized, dormant skin lesions (
 
Leishmania
 
 recidi-
vans), and the development of destructive mucocutaneous
leishmaniasis (espundia) months or years after healing of a
localized cutaneous ulcer (6, 7).
C57BL/6 mice (B/6) provide a good murine model for
cutaneous leishmaniasis because the pattern of infection
closely mimics the human disease. After inoculation of
 
Leishmania major
 
 parasites into B/6 mice, parasite expan-
sion is controlled by cellular immune mechanisms that also
mediate the development of a small cutaneous lesion that
heals spontaneously after a few weeks (8, 9). During the
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primary infection, 
 
L. major
 
 can be transiently detected in a
distal site (10). After reduction of the parasite burden and
lesion healing, the persistence of a small number of para-
sites is associated with the establishment of powerful im-
munity against reinfection, a state referred to as concomi-
tant immunity (1, 11, 12). Endogenous CD4
 
  
 
CD25
 
 
 
regulatory T (T reg) cells have been recently described as a
unique population of CD4
 
  
 
T cells that are able to prevent
autoimmune diseases by suppressing the activation and
expansion of self-reactive lymphocytes (13, 14). More
generally, they can be defined by their capacity to control
excessive or misdirected effector immune responses in-
cluding responses against other pathogens or self-antigens
(13, 15, 16). Using an intradermal low dose model of in-
fection, we have previously demonstrated that T reg cells
are essential for the development and maintenance of per-
sistent cutaneous infection with 
 
L. major
 
 (17). T reg cells
rapidly accumulate at sites of 
 
L. major
 
 infection, suppress-
ing the ability of the immune response to completely
eliminate the parasite. In this model, control of effector
functions occurs through both IL-10–dependent and –inde-
pendent mechanisms. Paradoxically, persistence of low
numbers of parasites during latent infection is required for
durable immunity against superinfection with 
 
Leishmania
 
at secondary sites.
Although powerful and durable immunity to reinfection
has been a consistent finding in mice and humans after
healing of their primary lesions, and remains the rationale
for live vaccination against cutaneous leishmaniasis, the
consequences of secondary challenge to the conditions that
maintain persistence in the primary site remain poorly un-
derstood. In this work, we show that when chronically in-
fected mice are challenged at a distant site, despite powerful
immunity to reinfection in the challenge site, transient re-
activation of parasite replication and dermal pathology oc-
curs at the primary site. Reactivation was associated with a
local increase in the number of CD4
 
  
 
CD25
 
  
 
T cells.
Depletion of CD25
 
  
 
cells at the time of the challenge
prevented disease reactivation at the primary site while
strengthening the expression of immunity in the challenged
site. Finally, the transfer of T reg cells purified from chron-
ically infected mice into chronically infected mice was suf-
ficient to trigger disease reactivation and prevent the
expression of effector memory response. Our results dem-
onstrate that although persistence is achieved, the equi-
librium between T reg cells and effector lymphocytes,
which could be disturbed in the case of superinfection,
controls the efficiency of recall immune response and dis-
ease reactivation.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B/6) mice were purchased from the Divi-
sion of Cancer Treatment, National Cancer Institute or Charles
River Laboratories. All mice were maintained in the National In-
stitute of Allergy and Infectious Diseases (NIAID) Animal Care
Facility or Cincinnati Children’s Hospital Research Foundation
under pathogen-free conditions.
 
Infection Protocol. L. major
 
 clone V1 (MHOM/IL/80/Fried-
lin) promastigotes were grown at 26
 
 
 
C in medium 199 supple-
mented with 20% Hi-FCS (Hyclone), 100 U/ml penicillin, 100
 
 
 
g/ml streptomycin, 2mM 
 
l
 
-glutamine, 40 mM Hepes, 0.1 mM
adenine (in 50 mM Hepes), 5 
 
 
 
g/ml hemin (in 50% triethanol-
amine), and 1 
 
 
 
g/ml 6-biotin (M199/S). Infective-stage promas-
tigotes (metacyclics) of 
 
L. major
 
 were isolated from 4–5-d-old sta-
tionary cultures by negative selection of infective forms using
peanut agglutinin (Vector Laboratories). Mice were infected in
the ear dermis with 500 or 1,000 
 
L. major
 
 metacyclic promasti-
gotes using a 27 1/2 G needle in a volume of 10 
 
 
 
l.
 
Parasite Quantitation.
 
Parasite loads in the ears were deter-
mined as described previously (9). In brief, the ventral and dorsal
sheets of the infected ears were separated and deposited dermal
side down in RPMI containing 100 U/ml penicillin, 100 
 
 
 
g/ml
streptomycin, and 50 
 
 
 
g/ml of liberase CI enzyme blend (Boeh-
ringer). Ears were incubated for 40 min at 37
 
 
 
C. The sheets were
dissociated in RPMI with 10% serum and 0.05% DNase I
(Sigma-Aldrich) using a medimachine (BD Biosciences) accord-
ing to the manufacturer’s instructions. The tissue homogenates
were filtered using a 70-
 
 
 
m cell strainer (Falcon) and serially di-
luted in a 96-well flat-bottom microtiter plate containing bipha-
sic medium, which was prepared using 50 
 
 
 
l NNN medium
containing 20% of defibrinated rabbit blood overlaid with 100 
 
 
 
l
M199/S. The number of viable parasites in each ear was deter-
mined from the highest dilution at which promastigotes could be
grown out after 7 d of incubation at 26
 
 
 
C. The number of para-
sites was also determined in the local draining LNs (retromaxilar).
The LNs were mechanically dissociated and parasite load in LN
cells was determined by limiting dilution as described above.
 
Analysis of Dermal Lymphocytes.
 
Single cell suspensions from
the ear dermis were obtained as described above. For the analysis
of surface markers and intracytoplasmic staining for IFN-
 
 
 
, cells
were stimulated with 
 
L. major
 
–infected bone marrow–derived
dendritic cells (BMDC) as a source of antigen for 16 h. The cells
were cultured for an additional 6 h with 10 
 
 
 
g/ml brefeldin A
(18), and then fixed in 4% paraformaldehyde. Before staining,
cells were incubated with an anti–Fc
 
 
 
 III/II receptor and 10%
normal mouse serum in PBS containing 0.1% BSA, 0.01% NaN
 
3
 
.
Cells were permeabilized and stained for the surface markers
CD3 (145-2 C11, FITC-labeled), TCR-
 
  
 
(H57-597), CD4
(GK1.5 cychrome-conjugated), and CD8 (RM4-5 and 53-6.7,
cychrome-conjugated), and for the cytokines IFN-
 
  
 
and IL-10
(clones XNG1.2 and JE56-5H4). Incubations were performed for
30 min on ice. The isotype controls used were rat IgG
 
2b 
 
(A95-1)
and rat IgG
 
2a 
 
(R35-95). All antibodies were purchased from BD
Biosciences. The frequency of CD4
 
  
 
and CD8
 
  
 
T cells was de-
termined by gating on CD3
 
  
 
or TCR-
 
 
 
  
 
cells. For each sample,
at least 100,000 cells were analyzed. The data were collected and
analyzed using CELLQuest™ software and a FACSCalibur™
flow cytometer (Becton Dickinson).
 
Cytokine Measurements.
 
For cytokine measurements in cul-
ture supernatants, pooled cells from draining LNs were resus-
pended in RPMI containing FBS/penicillin/streptomycin at 6 
 
 
 
10
 
6 
 
cells/ml, and 0.1 ml was plated in 96-well U-bottom plates.
Cells were incubated at 37
 
 
 
C in 5% CO
 
2 
 
with uninfected or 
 
L.
major
 
–infected BMDC for 48 h. In some experiments, dermal cell
suspensions were stimulated for 12 h with 10 
 
 
 
g/ml anti-CD28
(37.51; BD Biosciences), 25 
 
 
 
g/ml soluble leishmanial antigen,
and 5 ng/ml IL-2 (Endogen) as described previously (19). Cyto-
kine IFN-
 
 
 
, IL-10, IL-4, and IL-5 productions were analyzed us-
ing a mouse cytokine multiplex assay from Linco Research, Inc.
according to the manufacturer’s instructions. In brief, 25 
 
 
 
l of 
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cell supernatant was incubated with antibody-coated bead mix
for 16 h at 4
 
 
 
C. The beads were washed twice and incubated
with secondary biotinylated antibody mix for 1 h at room tem-
perature. Streptavidin-phycoerythrin was added and incubated
for an additional 30 min at room temperature. The beads were
washed three times, and then analyzed on a Luminex 100 plat-
form (Luminex Corp.). Cytokine concentrations were calculated
from standard curves.
 
T Cell Purification and Adoptive Cell Transfers.
 
CD4
 
 
 
 CD25
 
 
 
or CD4
 
  
 
CD25
 
  
 
T cells from mice chronically infected with 
 
L.
major
 
 were purified from ears and local draining LNs by cell sort-
ing as described previously (20). The T cell subsets were 
 
 
 
98%
pure as analyzed by flow cytometry. CD4
 
  
 
CD25
 
  
 
or CD4
 
 
 
CD25
 
  
 
T cells (2–5 
 
  
 
10
 
5
 
/mouse) were transferred i.v. to mice
that had been infected in one ear for 
 
 
 
3 mo. In some experi-
ments, mice were rechallenged with 1,000 metacyclic promasti-
gotes in the opposite ear at the time of the transfer. Mice receiv-
ing no cells were included as controls.
 
CD25
 
  
 
T Cell Depletion.
 
Mice were injected at the time of
secondary challenge with 1 mg anti-CD25 (PC6C1; American
Type Culture Collection [ATCC]) or isotype control (A1101-1;
ATCC) antibodies. Antibodies were produced using serum-free
medium (BD Biosciences) and a CELLine™ device (BD Bio-
sciences) according to the manufacturer’s instructions. Antibodies
were purified by protein G affinity chromatography (Pierce
Chemical Co.). The efficiency of depletion was monitored 2 d
after depletion by flow cytometry analysis of LN, spleen, and der-
mal cells using 7D4 antibody (anti-CD25). The efficiency of de-
pletion was 
 
 
 
80%.
 
Statistical Analysis.
 
Statistical analyses were performed using
GraphPad Prism software. Dual comparisons were made using
the unpaired Student’s 
 
t
 
 test. All data from parasite numbers were
log transformed before statistical tests were conducted.
 
Results
 
Rechallenge in a Distal Site Induces Disease Reactivation at
the Primary Site.
 
We have previously shown that during
the chronic phase of the infection a high number of both
effector lymphocytes (CD4
 
  
 
CD25
 
  
 
T cells, producing
IFN-
 
 
 
) and T reg cells (CD4
 
  
 
CD25
 
  
 
T cells, producing
IL-10) accumulate at sites of infection. A tight equilibrium
between the two populations is responsible for the mainte-
nance of parasite persistence (17). In this work, we exam-
ined the effect(s) of rechallenge in a distant site on the
equilibrium between effector T cells and T reg cells at pri-
mary sites of infection and consequently on pathology and
parasite burden.
B/6 mice were infected with 500 
 
L. major
 
 metacyclics in
one ear. This primary challenge resulted in a transient pa-
thology (Fig. 1 B) that coincided with parasite control (Fig.
1 C). The acute phase of the infection was followed by es-
tablishment of a chronic phase, characterized by the stable
maintenance of a low number of parasites at the inoculated
site (latent site, 
 
 
 
5 
 
  
 
10
 
3 
 
parasites per ear; Fig. 1 C) and its
draining LN in the absence of overt pathology (17, 21). At
12 wk after challenge, mice were injected in the opposite
ear (challenged ear) with 500 
 
L. major
 
 metacyclics as shown
in Fig. 1 A. Chronically infected mice were immune to re-
infection, as evidenced by the rapid control of parasite
number at the challenged site and by the fact that no pa-
thology was detected (Fig. 1, B and C). Interestingly, not
all of the parasites were eliminated from the dermis of the
challenged site, as a low number of parasites were still
present at 11 wk after challenge (250 parasites/ear; Fig. 1
C). Surprisingly, the expression of concomitant immunity
was associated with reactivation at the primary site. Disease
reactivation occurred between 3 and 6 wk after challenge
and was manifested by (a) moderate increased lesion size
(Fig. 1 B), (b) strong inflammation, as shown by the accu-
mulation of neutrophils and eosinophils (not depicted), and
(c) parasite expansion (from 2 
 
  
 
10
 
3 
 
to 6 
 
  
 
10
 
5 
 
at 3 wk af-
ter challenge; Fig. 1 C). At 6 wk after challenge, parasite
persistence was reestablished in the reactivated site, with
maintenance of a small number of parasites in absence of
any detectable pathology.
 
Reactivation of the Chronic Site upon Secondary Challenge
Correlates with a Local Increase in CD4
 
  
 
CD25
 
  
 
T Cells.
 
The numbers of CD4
 
  
 
CD25
 
  
 
and CD4
 
  
 
CD25
 
  
 
T cells
were analyzed at different time points in both primary and
secondary sites (Fig. 2 A). The number of CD4
 
  
 
CD25
 
  
 
T
Figure 1. Challenge in a distal site with L. major induces disease reacti-
vation of L. major latent site. (A) B/6 mice were infected in the ear with
500 L. major metacyclic promastigotes. At 12–15 wk, chronically infected
mice were challenged in the other ear with 500 L. major metacyclic pro-
mastigotes. The disease outcome was followed up to 12 wk after secondary
challenge. (B) Lesion size, expressed as mean induration   SD, 3–10 mice
with 6–20 ears per group. (C) Parasite number per ear, expressed as geo-
metric mean   SD, six ears per group. **, statistically significant between
primary and secondary ear (P   0.01);  , primary site;  , secondary site.Superinfection of Mice Immune to L. major Reactivates Persistent Infection 204
cells increased in the primary site during lesion reactiva-
tion (from 3   104   5.7   103 before secondary chal-
lenge to 5.4   104   6   103 at 3 wk after challenge). The
number of CD4  CD25  T cells was sustained during re-
activation at the primary site (between the third and sixth
weeks after challenge), and then decreased at 12 wk after
challenge. In contrast, the number of CD4  CD25  T
cells did not increase significantly in the challenged site
(Fig. 2 A).
Before secondary challenge, CD4  T cells producing
IFN-  in response to Leishmania antigen were only detect-
able in the primary site of infection (Fig. 2 B). After rechal-
lenge, the number of CD4  IFN-   cells increased in the
challenged site during parasite killing (threefold increase at
6 wk after infection; Fig. 2 B). Surprisingly, this accumula-
tion of a higher number of IFN- –producing CD4  T cells
occurred at the primary site during reactivation as well
(threefold increase at 6 wk after challenge; Fig. 2 B). The
intradermal lymphocyte able to produce IFN-  remained
CD25 low or dim even after in vitro restimulation (not de-
picted). The IL-10–producing CD4  T cells were only de-
tectable in the primary site before secondary challenge
(4.5   103   6.2   102 cells per ear; Fig. 2 C). Reactiva-
tion also correlated with a significant increase in the num-
ber of IL-10–producing CD4  T cells (threefold increase at
6 wk after challenge; Fig. 2 C). Interestingly, the accumu-
lation of CD4  IL-10  paralleled the kinetics of accumula-
tion of the IFN- –producing CD4  cells. In contrast, the
number of IL-10–producing CD4  cells remained low in
the secondary site (below 102 per ear at every time point
analyzed; Fig. 2 C).
Figure 2. Increased frequency of dermal CD4  CD25  T cells, CD4 
IFN- , and CD4  IL-10–producing cells during reactivation. Mice were
infected in one ear with 500 L. major promastigotes. After clinical cure,
mice were challenged in the other ear with 500 L. major promastigotes.
Absolute number at primary ( ) and secondary site ( ) of (A) CD4 
CD25  T cells, (B) CD4  IFN- –producing cells, and (C) CD4  IL-10–
producing cells at different time points after secondary challenge. (A) Abso-
lute  number of CD3  CD4  cells per ear expressing CD25 compared
with isotype control. Isolated cells were stained for surface markers and
analyzed by flow cytometry. (B and C) Absolute number of CD3  CD4 
cells per ear expressing IFN-  and IL-10. Dermal cells were incubated
overnight with L. major–infected BMDC before labeling for surface
markers and intracellular cytokines. Values represent the mean of the ab-
solute number of cells per ear   SEM. Dermal cells from four mice per
time point were analyzed individually. *, statistically significant between
day 0 and the time point analyzed (*, P   0.05; **, P   0.01). This ex-
periment is representative of three distinct experiments.
Figure 3. Transfer of T reg cells triggers disease reactivation. Chroni-
cally infected B/6 mice were transferred i.v. (or not) with 5   105 T reg
cells or CD4  CD25  T cells from previously infected mice. (A) Parasite
numbers at primary sites 4 wk after transfer, with four mice per group. **,
statistically significant between control mice and mice transferred with T
reg cells (P   0.01). (B) Dermal CD4  IFN-  (open bars) and CD4  IL-10–
producing cells (closed bars) at 4 wk after transfer. Purified dermal cells
were incubated overnight with L. major–infected BMDC before labeling
for surface markers and intracytoplasmic staining for cytokines. Numbers
represent the absolute number of CD4  TCR-   IFN-   or IL-10  per
ear. Dermal cells from six or eight ears were pooled. This experiment is
representative of three distinct experiments.Mendez et al. 205
Transfer of T reg Cells Triggers Reactivation of Latent Infec-
tions. We directly assessed the role of T reg cells in disease
reactivation by transferring into chronically infected mice
either CD4  CD25  or CD4  CD25  T cells purified from
previously infected, healed mice. This transfer was per-
formed in the absence of additional parasitic challenge. The
adoptive transfer of T reg cells into chronically infected
mice led to a marked increase in CD4  CD25  T cell
numbers at the site of primary infection (2.5-fold increase;
not depicted). This increase consistently correlated with
parasite replication and disease reactivation (Fig. 3 A). The
transfer of CD4  CD25  triggered reactivation in some an-
imals and was inconsistent among the different experiments
(Fig. 3 A). Reactivation induced by T reg cell transfer was
accompanied by a significant increase of both IL-10 and
IFN-  production by dermal CD4  T cells (over threefold
increase at 4 wk after challenge; Fig. 3 B). A similar pattern
was observed for cytokine production by local LN cells
(not depicted). Such increases in cytokine production were
not observed after the transfer of CD4  CD25  T cells.
Moreover, the level of IL-4 production by LN cells was
negligible during disease reactivation (not depicted). These
data indicate that adoptive transfer of T reg cells from in-
fected mice was sufficient to trigger powerful reactivation
of primary infection.
CD25  Cell Depletion Strengthens the Intensity of the
Immune Response and Prevents Reactivation. Because the
adoptive transfer of T reg cells consistently induced dis-
ease reactivation, we treated chronically infected mice
with a depleting anti-CD25 antibody at the time of chal-
lenge. The depletion of CD25  cells at the time of the
secondary challenge significantly prevented disease reacti-
vation in the primary site (Fig. 4 A). Interestingly, such
depletion also enhanced the efficiency of the effector im-
mune response, with a better control of the parasite repli-
cation in the challenge site at 3 wk after challenge (1.1  
102 for anti-CD25–treated mice compared with 5.1   104
parasites per ear for isotype-treated mice; Fig. 4 A). The
higher dose of parasites used in this experiment induced a
more rapid reactivation and immune response at the chal-
lenge site.
As previously described, the chronic site is characterized
by the accumulation of CD4  T cells. Anti-CD25 treat-
ment significantly increased the influx of CD4  T cells at
both primary and challenged sites (Fig. 4 B) after 1.5 wk.
At 4.5 wk after challenge, a time when the isotype-treated
mice had restored homeostatic conditions in both latent
and challenged sites, CD25 depletion was accompanied
with the maintenance of a high number of CD4  T cells at
both sites. In addition, CD25 depletion allowed for the sus-
Figure 4. Anti-CD25 treatment prevents disease reacti-
vation and strengthens the intensity of immune response.
Chronically infected B/6 mice were challenged in the oppo-
site ear with 103 L. major promastigotes and treated at the
same time with anti-CD25 or isotype control Abs. (A) Para-
site number at 3 wk after challenge in mice treated with
anti-CD25 or isotype Abs as indicated. **, statistically sig-
nificant (P   0.01). (B) Number of lymphocytes per ear in
primary, latent, and rechallenged dermal site at 1.5 and 4.5
wk. Mice were treated with anti-CD25 or isotype control
as indicated. Values represent the mean number of lym-
phocyte per ear   SEM, four mice per group. *, statisti-
cally significant between isotype and anti-CD25 treatment
(**, P   0.01; ***, P   0.001). (C) CD4  IFN-   cells in
the dermis of challenged mice. Dermal cells were incu-
bated with L. major–infected BMDC before labeling for
surface markers and intracellular IFN- . Plots shown are
gated on TCR-   lymphocytes. Numbers in the top right
quadrant represent the percentage of CD4  TCR-   T
cells positive for IFN-  compared with the isotype control.
Ears from four animals were pooled. This experiment is
representative of three distinct experiments.Superinfection of Mice Immune to L. major Reactivates Persistent Infection 206
tained production of IFN-  by intradermal CD4  T cells in
both latent (44% of CD4  T cells compared with 17% in
isotype-treated mice) and challenged sites (50% compared
with 20%) at 4.5 wk after challenge (Fig. 4 C). Thus, a
transient depletion of CD25  cells at the time of the trans-
fer was sufficient to prevent disease reactivation in the pri-
mary site and to intensify and prolong the local immune re-
sponse at the challenged site.
T reg Cells from Chronically Infected Mice Suppress Immunity
at Sites of Rechallenge. To confirm that T reg cells are re-
sponsible for controlling the efficiency of the effector re-
sponse after secondary challenge, we assessed the expression
of immunity in mice transferred with T reg cells. Chroni-
cally infected B/6 mice were transferred with either CD4 
CD25  or CD4  CD25  T cells, each obtained from pre-
viously infected and healed mice, and challenged in the op-
posite ear with 1,000 L. major parasites. At 4 wk after chal-
lenge, parasite burden was evaluated at the challenged site.
Mice transferred with T reg cells lost their capacity to con-
trol parasites in the challenged site, whereas mice trans-
ferred with CD4  CD25  cells or not transferred were
immune to secondary challenge as expected (Fig. 5 A).
Analysis of the cytokine released by dermal cells from the
challenge site revealed that at 1 wk after challenge, T reg
cell transfer led to an increase of the IL-10 production at
the challenged site (from 430   57 to 1,230   220 pg/ml).
At 4 wk after transfer, the production of IFN- , IL-5, and
IL-4 was significantly increased at the challenge site com-
pared with control mice or mice transferred with CD4 
CD25  (Fig. 5, B and C). These results confirm that up-
regulation of the number of T reg cells at the time of the
challenge has detrimental consequences on the efficiency of
the local effector immune response.
T reg Cell and Effector Lymphocytes Migrate in Both the Pri-
mary and Immune Sites during Rechallenge. We have shown
that when effector immune response occurs, the number of
T reg cells do not increases in the challenge site. On the
other hand, T reg cells were able to interfere with concom-
itant immunity, suggesting that early after challenge they
have the capacity to enter in the challenge site. To address
this point, chronically infected B/6 mice were transferred
with either CD4  CD25  or CD4  CD25  T cells, each
obtained from previously infected and healed congenic
Ly5.1 mice, and challenged in the opposite ear with 1,000
L. major parasites. At 1 wk after transfer and challenge, a
similar number of T reg cells and CD4  CD25 , identified
by their expression of congenic marker, were detected in
the primary or secondary site of infection (Fig. 6). Interest-
ingly, T reg cells from infected mice were able to enter in
the primary site even in the absence of secondary challenge
(3.2   104   1.5   104 in the primary site, 1 wk after
transfer of 5   105 T reg cells). T reg cells or CD4  CD25 
cells purified from naive mice were not detectable after
transfer in the challenged or chronic site at 1 wk after in-
fection (not depicted). Thus, early after challenge, T reg
cells and effector cells entered with similar efficiency in
both sites.
Discussion
We have previously shown that the establishment of
chronicity and the maintenance of a constant number of
parasites at sites of infection were dependent on a tight
equilibrium between effector lymphocytes and T reg cells
(17). Absence or inhibition of T reg cells or IL-10 will pro-
Figure 5. Transfer of T reg cells prevents parasite control in immune
mice. B/6 mice were infected in one ear with 500 L. major promastigotes.
After clinical cure, mice were challenged in the other ear with 103 L. major
promastigotes. At the time of secondary challenge, 5   105 T reg cells or
CD4  CD25  T cells purified from latently infected mice were adoptively
transferred or not as noted. (A) At 4 wk after infection, parasite numbers
were assessed in the challenged site. Numbers represent mean parasite
burdens per ear   SD, four mice per group. **, statistically significant
compared with primary challenge (P   0.01); n.s, nonsignificant com-
pared with primary challenged. (B and C) Measure of cytokine release by
dermal cells at 4 wk after challenge. IFN- , IL-10, IL-4, and IL-5 were
measured in the supernatant of dermal cells activated with anti-CD28, IL-2,
and soluble leishmanial antigen. Values represent the mean cytokine con-
centration   SEM, four mice per group. *, statistically significant com-
pared with secondary challenge control (*, P   0.05; ***, P   0.001). The
data shown are representative of two distinct experiments.Mendez et al. 207
mote complete clearance of the parasite, whereas depletion
of effector cells or cytokines (e.g., IFN- , IL-12) will pro-
mote reactivation (1, 22, 23). In this work, we introduce
an alternative and surprising condition that perturbs the
maintenance of the chronic state. We show that when la-
tency is achieved, the expression of immunity to a rechal-
lenge infection in a distant site is associated with reactiva-
tion of disease at the primary site of infection.
A cross talk between the primary and secondary sites of
infection has been previously reported. Preston and Du-
monde (24), using various doses of infection, demonstrated
that secondary challenge could impair the healing of the
primary site during Leishmania infection. Furthermore,
Muller (25) showed that a transient increase in footpad
swelling of the healed primary site occurred after secondary
challenge with the parasite. Our present results strongly
suggest that the introduction of antigen in a secondary site
initiates a disruption of the equilibrium between the two
populations of lymphocytes in favor of T reg cells that are
responsible for disease reactivation. This hypothesis is sup-
ported by the fact that reactivation (a) correlates with an in-
crease in T reg cells at the primary site, (b) can be repro-
duced by the transfer of T reg cells from chronically
infected mice, and (c) is prevented by the depletion of
CD25  cells. Furthermore, we showed that depletion of
CD25  cells strengthens the efficiency of effector mecha-
nisms during memory response, whereas the transfer of T
reg cells at the time of rechallenge prevented the expression
of such immunity.
CD4  CD25  T reg cells, which constitute 5–10% of
peripheral CD4  T cells in normal rodents and humans at
steady-state conditions, have been primarily described for
their fundamental role in the control of autoimmunity.
More generally, T reg cells can be defined by their role in
the control of excessive or misdirected immune responses
(for review see references 13 and 16). There is growing ev-
idence that T reg cells play a significant role in microbial
infection (26–30). Our demonstration that T reg cells are
increased in number and play a role in the reactivation of
dormant infection after reinfection seems highly relevant to
clinical settings because individuals with persistent Leishma-
nia infections will, in many instances, be reexposed to the
parasite. The data seems especially relevant to certain reac-
tivation diseases like Leishmania recidivans or post-kala-azar
dermal leishmaniasis that in each case represent spontane-
ous reactivation of cutaneous lesions in previously cured
individuals (4, 6). Although CD25 is also expressed on re-
cently activated T cells, the observation that the number of
CD4  CD25  T cells do not increase during the expression
of immunity at the secondary site strongly suggests that in
the cutaneous site, only T reg cells express high level of
CD25. This is further supported by our previous observa-
tion that the vast majority of the cells expressing CD25 at
sites of infection were derived from endogenous T reg cells
(17). During the early phase of L. major infection, the para-
site is transiently detected in distant cutaneous sites (10).
Such even may occur in the context of a secondary chal-
lenge and contribute to the initiation of the reactivation
process. Although we cannot rule out the possibility that
the increase of T reg cells observed in the context of super-
infection is not the cause but a consequence of the reacti-
vation process, the transfer of T reg cells was sufficient to
consistently trigger disease reactivation. Furthermore, the
depletion of CD25  cells at the time of the rechallenge pre-
vented such reactivation.
Our results suggest that the numbers of T reg cells that
are present at the time of the recall response are directly re-
sponsible for the efficiency of the effector immune re-
sponses. A depletion of CD25  T cells at the time of the
challenge was sufficient to enhance the efficiency of the re-
call response. The rapid control of parasite charge after de-
pletion of CD25  T cells was associated with a significant
increase of the early influx of CD4  T cells in the chal-
lenged site as well as their sustained accumulation com-
pared with control mice. Furthermore, we observed an en-
hanced and sustained capacity of CD4  T cells to produce
IFN-  in response to Leishmania antigen after CD25  cell
depletion. Although a decrease of T reg cells led to en-
hanced parasite control, the adoptive transfer of exogenous
T reg cells from latently infected mice was able to hamper
the efficiency of the recall responses. The mechanism by
which an excess of T reg cells control concomitant immu-
nity is not fully understood, but might be at least partially
Figure 6. T reg cells and effector cells migrate at sites of infection. B/6
mice were infected in one ear with 500 L. major promastigotes. After clinical
cure, mice were challenged in the other ear with 103 L. major promastigotes.
At the time of secondary challenge, 5   105 T reg cells or CD4  CD25 
T cells purified from healed congenic (Ly5.1) infected mice were adop-
tively transferred or not as noted. At 1 wk after infection, the number of
Ly5.1  cells in the primary or challenged site was evaluated by flow cytome-
try. Values represent the number of TCR- , CD4, and Ly5.1  cells per
ear, with four mice per group. The data shown are representative of two
distinct experiments. n.s, nonstatistically significant between the experi-
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explained by their capacity to rapidly accumulate at chal-
lenge site and promote local IL-10 production. Although T
reg cells are not a significant source of IL-4 or IL-5, or
IFN-  in response to Leishmania antigen (17), their transfer
also led to a marked increase in the production of those cy-
tokines at the challenge site. Thus, T reg cell transfer led to
a profound modification of the local microenvironment in
favor of cytokines known to promote parasite expansion
(31, 32). All together, those results demonstrate that even
in immune mice, in which effector mechanisms are more
efficient than during primary challenge, T reg cells can
control the intensity of the recall response.
We have shown that during recall responses, the number
of T reg cells increased at reactivated sites while it de-
creased in challenged sites. This result is consistent with our
previous report indicating that T reg cells, compared with
effector cells, are preferentially attracted to sites of L. major
infection during parasite expansion and after clinical cure.
In contrast, the proportion of effector cells increased during
the effector immune response (17). Differences in chemo-
kine responsiveness or receptor expression between T reg
cells and effector T cells have been shown previously in
various models (33–35). Therefore, a plausible explanation
for the coexpression of immunity and reactivation would
be that upon pathogen reexposure, both populations of
lymphocytes expand, but that their pattern of trafficking is
distinct. To maintain homeostasis, the chronic site would
preferentially attract and favor the survival of T reg cells,
whereas effector T cells would be preferentially attracted to
the proinflammatory challenged site. A nonexclusive possi-
bility would be that the migration of T reg cells or effector
cells in distinct sites produce a distinct outcome. In the
chronic site, effector cells would not be able to overwrite T
reg cell–mediated deactivation of infected APCs, whereas
T reg cells will further deactivate the site favoring parasite
replication. In the challenged site, the rapid arrival/expan-
sion of effector cells could more efficiently activate local
APCs, leading to an amplification of the effector immune
response, inhibition of T reg cell suppressive functions (36–
38), and parasite killing. Consistently with this hypothesis,
using adoptive transfer model we have shown that early af-
ter challenge, both populations were able to migrate to pri-
mary and secondary sites of infection. The production of
IFN-  was increased in both sites, suggesting that effector
T cells were recruited at latent and challenged sites. Fur-
thermore, CD25  cell depletion enhanced the efficiency of
the recall response, an effect that supports their presence at
the challenged site. The signals to which T reg cells are ac-
tually responding upon arrival in infected tissue remain to
be addressed. A proportion of T reg cells may respond to
Leishmania antigen, as our previous studies showed that a
significant proportion of T reg cells in latent sites were
Leishmania antigen specific (17). On the other hand, some
T reg cells could also respond to cytokines such as IL-2 (a
cytokine that is required for their generation and survival;
39, 40), which memory effector cells would rapidly pro-
duce after antigen exposure.
During the reactivation process that occurs after superin-
fection or after T reg cell transfer, the production of IL-10
by dermal and LN CD4  T cells was significantly increased.
A role for IL-10 in mediating Leishmania susceptibility in
both susceptible and resistant strains is well established (19,
41–44). We have previously shown that IL-10, which is
produced by T reg cells, contributes directly to parasite
persistence (17). The mechanism(s) by which IL-10 allows
parasite survival and expansion are not fully understood,
but it is likely due to its potent deactivating role of infected
APCs that would become unresponsive to activation by
IFN-  (45). During disease reactivation, IFN-  production
was increased, suggesting that effector T cell functions are
not suppressed. In the presence of deactivating cytokines or
in the absence of secondary signals, IFN-  can itself pro-
mote parasite expansion (32). These results support the idea
that during the reactivation process, deactivation mediated
by IL-10–producing T reg cells prevails over effector mech-
anisms. Such principals appear to apply to various models of
infection including Leishmania donovani and Schistosoma man-
soni, in which the levels of a deactivating cytokine such as
IL-10 (but not IFN- ) predict the outcome of the infec-
tion (46–48).
Reactivation or activation of latent infections with bac-
teria (e.g., Mycobacterium tuberculosis), protozoa (e.g., Leish-
mania spp., Toxoplasma), and viruses (e.g., herpes viruses)
causes an immense burden of morbidity and mortality in
the world at large. Reactivation can occur as a result of im-
munosuppression, environmental insults, or with advancing
age (49, 50); however, a definite cause for the reactivation
or primary activation of dormant infections is often not
clear. In this work we have shown that despite efficient
parasite clearance at the secondary site of infection, Leish-
mania superinfection can also cause disease reactivation at
the primary site. Such coexpression in the same animal of
immunity versus disease reactivation may provide for a
more general mechanism by which some dormant infec-
tions are activated or reactivated.
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